Business
Leyden Labs secures EUR 40m to advance intranasal antibody defense against respiratory viruses
Netherlands-based Leyden Laboratories B.V. (Leyden Labs) announced a €40 million (approximately USD 43.6 million) private placement from a geographically...
Ionis signs ex-US zilganersen licensing deal with Recordati ahead of FDA decision
Ionis locks in a USD 30 million upfront payment and tiered royalties of up to the mid-20% range from Italy-based Recordati (Milan: REC) for exclusive ex-US...
Sangamo files for bankruptcy as Lilly and Astellas become stalking horse bidders for gene therapy assets
Richmond, California-based Sangamo Therapeutics, Inc. (OTCQB: SGMO) has entered into two separate asset sale agreements with Eli Lilly and Astellas Pharma,...
CalciMedica pivots toward pulmonary hypertension with USD 49m financing round
La Jolla, California-based CalciMedica, Inc. (Nasdaq: CALC) announced a private placement of up to approximately USD 49 million to pivot the company's...
MoonLake boosts public offering to USD 200m for sonelokimab
Switzerland-based MoonLake Immunotherapeutics (Nasdaq: MLTX) announced the pricing of an upsized underwritten public offering of Class A ordinary shares and...
uniQure upsizes public offering to USD 225m
Lexington, Massachusetts-based uniQure N.V. (Nasdaq: QURE) announced the pricing of an upsized underwritten public offering of ordinary shares, raising USD...
Trimtech raises USD 47m for TRIM21-targeted protein degradation in neurodegeneration
UK-based TRIMTECH Therapeutics has closed an additional USD 14 million in seed funding, bringing its total seed round to USD 47 million (£35 million), as...
Rapalogix secures USD 20m to advance TORC1-targeting skincare and prescription dermatology pipeline
Carlsbad, California-based Rapalogix Health, a biotechnology company developing TORC1-targeting therapeutics and professional skincare products for skin...
Ollin secures USD 330m to advance VEGF/Ang2 BsAb after beating Vabysmo head-to-head
Austin, Texas-based Ollin Biosciences, Inc. has closed an oversubscribed USD 330 million Series B financing round to fund global Phase III development of...
Definium secures USD 700m in upsized offering for psychedelic pipeline
New York-based Definium Therapeutics, Inc. (Nasdaq: DFTX) announced the pricing of an upsized underwritten public offering of common shares, raising...
Merck KGaA, Versant launch Saturnus Bio in USD 50m rare cardiology venture
Saturnus Bio, a precision cardiology company founded by Versant Ventures, has launched with USD 50 million in upfront funding from Merck as part of a...
NorthLinks Bio launches with USD 34m from RA Capital to advance intranasal antiviral HEX17
Boston-based NorthLinks Bio has launched with USD 34 million in financing from RA Capital Management to advance its intranasal prophylactic antiviral...
Osanni Bio secures USD 190m to scale platform across ophthalmology and cardiology programs
San Francisco-based Osanni Bio LLC has closed a USD 190 million Series B financing round to advance its multi-therapeutic platform, with active programs in...
Definium raises USD 500m to push psychedelic-derived DT120 toward psychiatric disorder approval
New York-based Definium Therapeutics, Inc. (Nasdaq: DFTX) announced a proposed underwritten public offering of USD 500 million in common shares and, to...
Genetix expands gene therapy footprint into Middle East with SPIMACO manufacturing deal
Somerville, Massachusetts-based Genetix Biotherapeutics has struck an exclusive licensing and commercialization agreement with Saudi-based Saudi...
The AllSci Brief
Systematic R&D and deal news. Daily.